However, chronic MP treatment could mimic the pharmacokinetic profile of treated ADHD patients due to the blockage of the dopamine transporter (DAT) and norepinephrine transporter (NET) and the increased monoamine levels in the synapse. Here, SLC6A2 is linked to attention deficit-hyperactivity disorder.